Enso Ventures

Cognitive Geology Ltd, established in 2014 and based in Edinburgh, UK, specializes in developing advanced geological modeling software for the oil and gas industry. The company's innovative tools help geologists systematically analyze and mitigate the impacts of various geological processes, aiding in the discovery, appraisal, and development of both conventional and unconventional reserves, both onshore and offshore.

Neurovia, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, founded in 2013. The company focuses on developing therapies for neurological disorders, specifically targeting unmet medical needs in conditions such as X-linked adrenoleukodystrophy (X-ALD). Neurovia has created a selective thyromimetic agent aimed at treating X-ALD, a rare genetic disease that can lead to severe neurological deficits. By addressing these critical health challenges, Neurovia aims to improve the quality of life for patients affected by this condition.

UltraSoC Technologies Ltd., established in 2005 and headquartered in Cambridge, UK, specializes in semiconductor intellectual property (IP) for system monitoring, analysis, and optimization. The company's core offering is an independent, non-intrusive system-level architecture that enables real-time, wire-speed monitoring of System-on-Chip (SoC) internal behavior. This IP accelerates and de-risks development by providing engineers with insights into complex interactions between on-chip sub-systems, buses, and software. UltraSoC's toolkit comprises configurable modules and software for IP configuration, debug, and analytics, serving applications in SoC debug, analytics and optimization, in-field monitoring, and security. Since June 2020, UltraSoC operates as a subsidiary of Siemens AG.

Cavion LLC is a clinical-stage pharmaceutical company focused on developing therapies that restore the brain’s natural rhythms by modulating T-type calcium channels (Cav3), which are implicated in various neurological and rare genetic diseases. The company, founded in 2003 and based in Charlottesville, Virginia, with an additional office in Cambridge, Massachusetts, has developed CX-8998, a drug that targets these calcium channels in the nervous system. Cavion's innovative approach also extends to cancer treatment, as the company was the first to create therapies that engage Cav3 for solid tumors, with preclinical successes leading to Phase 1 clinical trials in brain cancer. The company's neurology program aims to deliver a novel class of non-addictive, non-opioid T-type calcium channel antagonists for conditions like neuropathic pain, essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. Cavion operates as a subsidiary of Jazz Pharmaceuticals plc, reflecting its commitment to advancing treatments that address critical medical needs in both oncology and neurology.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, dedicated to developing innovative therapeutics aimed at enhancing the effectiveness of radiotherapy for cancer patients. The company's lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer. Additionally, GC4419 is being evaluated in Phase IIa trials for the treatment of radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing another candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. The company's research is focused on targeting oxygen metabolic pathways to improve patient outcomes in radiation therapy, and GC4419 has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

SRJ Technologies Group is an engineering company based in Jersey that specializes in the development and distribution of weld-free coupling and leak containment solutions for pipeline and process pipework systems. Founded in 2011 and headquartered in St Helier, the company offers a variety of innovative products, including mechanical couplings, repair clamps, and bespoke enclosure repair units, catering to industries such as oil and gas, desalination, mining, utilities, shipping, and power generation. SRJ Technologies Group's expertise is supported by a UK-based research and development team with over fifty years of experience in fittings manufacture. The company holds an exclusive license for the Snap Ring Joint, a revolutionary pipeline coupling system, and has achieved Type Approval for hydrocarbons service from Lloyds Register and ABS. In addition to its product offerings, SRJ provides Asset Integrity Management consulting services to assist asset owners in developing effective integrity strategies.

Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Cellectar Biosciences is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cancer treatment. The company's lead candidate, CLR 131, is a phospholipid drug conjugate (PDC) currently undergoing Phase II clinical trials for patients with relapsed or refractory multiple myeloma and other B-cell malignancies. Additionally, Cellectar is developing CLR 1900, a PDC aimed at targeting solid tumors. The company employs a proprietary PDC delivery platform, which combines lipid-like molecules with radioisotopes to enhance the targeting of malignant cells while minimizing effects on healthy tissue. Cellectar has established collaborative programs with various organizations to advance the development of multiple PDCs, further expanding its portfolio. Founded in 2002 and originally named Novelos Therapeutics, Cellectar Biosciences is headquartered in Florham Park, New Jersey.

Cambridge Nanotherm Limited is a company based in Haverhill, United Kingdom, specializing in the development and commercialization of advanced nano-ceramic technology for the electronics industry. Founded in 2010, the company focuses on thermal management solutions, particularly for LED applications and electronic substrates. Its primary product is the NANOTHERM metal-backed printed circuit board, which features a unique nano-ceramic dielectric layer applied directly to the surface of aluminum substrates. This innovative technology enhances thermal conductivity and dielectric strength, making it ideal for electronic interconnections. Additionally, Cambridge Nanotherm offers a chip-on-heat sink design specifically tailored for LED light engines, further solidifying its position in the thermal management market.

Carbodeon is a Finnish company specializing in the production of advanced nanomaterials. They primarily focus on two key products: uDiamond®, which are nanodiamond particles designed to enhance the toughness and durability of various materials, particularly in metal plating and low-friction coatings; and Nicanite®, a graphitic carbon nitride that can be converted into unique film coatings with superior thermal and mechanical properties. These nanomaterials are used to improve the lifetime and conductive performance of industrial components and appliances.